Research
Healthcare
lf0’s Healthcare hub collects every equity research note on medical device and diagnostics companies, where regulatory approval cycles, reimbursement dynamics, and innovation pipelines drive long-run returns more than quarterly noise. Coverage in this sector currently includes Abbott Laboratories (ABT), Boston Scientific (BSX), and Intuitive Surgical (ISRG). lf0 revisits these names periodically as new clinical data, product launches, and competitive dynamics reshape the investment case, so each company’s archive is organized chronologically rather than as a single static snapshot.





The Scorecard: 2 Month Update: SDGR Sell — Incorrect so far
Revisiting our Sell call on SDGR: entry $17.40, latest $22.60, +29.9%.
The Scorecard: 2 Month Update: STXS Sell — Correct so far
Revisiting our Sell call on STXS: entry $1.39, latest $1.05, -24.5%.
The Scorecard: 2 Month Update: NUTX Buy — Correct so far
Revisiting our Buy call on NUTX: entry $188.41, latest $200.80, +6.6%.
Boston Scientific Stock Analysis: Buy or Sell? Valuation & Growth Outlook
Boston Scientific (BSX) is rated Hold as strong organic growth and clinical momentum are offset by a valuation that already reflects much of the upside.…
The Scorecard: 4 Month Update: BSX Buy — Incorrect so far
Revisiting our Buy call on BSX: entry $46.76, latest $43.00, -8.0%.
Stryker Stock Analysis: Buy or Sell? Valuation, Margins & Risk
Stryker (SYK) is a HOLD as strong margins and free cash flow support the business, but the valuation already discounts much of that quality. Execution…
The Scorecard: 2 Month Update: OWLT Sell — Correct so far
Revisiting our Sell call on OWLT: entry $5.81, latest $4.73, -18.6%.
Ironwood Pharmaceuticals Stock Analysis: Buy or Sell? FCF, Valuation, Pipeline
Ironwood Pharmaceuticals (IRWD) is rated Hold as LINZESS continues to generate real free cash flow, but apraglutide has faced delays and the stock already reflects…
PACS Group Stock Analysis: Buy or Sell? Leverage, Valuation & Growth
PACS Group Inc. (PACS) is rated Hold as growth remains solid but leverage keeps the stock from looking cheap. Revenue is expanding, yet the balance…
The Scorecard: 2 Month Update: WGS Sell — Correct so far
Revisiting our Sell call on WGS: entry $77.88, latest $67.73, -13.0%.
Most Popular Research